Skip to main content
. 2016 Jun 1;32(6):547–560. doi: 10.1089/aid.2015.0264

Table 2.

Effect of Follicular Versus Luteal Phase on Study Endpoints

  FOL phase in S119 and S124 studies (n = 39) LUT phase in S119 and S124 studies (n = 39)    
Variable (units) Mean SD Mean SD Unadjusted p-value Adjusted p-value*
Antimicrobial activity of the CVL (% Inhibition)
 HSV-2 inhibition 42.6 33.5 51 31.2 .24 .24
E. coli inhibition 18.2 43.3 32.4 45.1 .32 .12
 HIV inhibition 17.6 49.3 14.3 48.3 .99 .76
p24 antigen production from vaginal (S119) or ectocervical (S124) tissue biopsies (pg.ml × mg tissue)
 p24_0 1.7 2.2 1.9 2.7 .32 .71
 p24_7 27.6 33.4 54.8 123 .42 .17
 p24_14 41.7 51.1 72.5 133.1 .61 .15
 p24_21 97 254.1 81.8 155.1 .63 .74
 p24_Soft 83.4 241.9 79.6 154.2 .87 .94
 p24_Cum 168.1 287.1 211 379.4 .77 .53
 p24_Max 105.9 253.5 95.2 168.7 .85 .82
 p24_AUC 831 1176.7 1183.8 2140.8 .70 .32
Immune cell populations (cells/mm2) in the EPI and LP and vaginal tissue histology
 Epithelial thickness (μm) 273 102.4 312.8 112.4 .14 .08
 Number of cell layers 24.5 6.5 26.7 7.5 .42 .07
 CD45 EPI 120.8 60.5 95.5 41.7 .63 .07
 CD45 LP 75 39.2 69.4 35 .41 .55
 CD3 EPI 87.3 44.1 70.2 33.2 .99 .15
 CD3 LP 47.1 29.6 46.4 26.7 .41 .91
 CD8 EPI 59.7 33.1 49.8 25.2 .99 .12
 CD8 LP 31.3 24.7 29.7 17.7 .61 .78
 CD4 EPI 0 0 0.1 0.3 .50 .17
 CD4 LP 2.3 4 2.2 3.5 .65 .93
 CCR5 EPI 0 0 0 0.2 .99 .30
 CCR5 LP 3.3 4.9 3.4 5 .84 .91
 HLADR EPI 45 26 51.1 33.3 .62 .35
 HLADR LP 36.1 24.5 41.5 23.3 .50 .27
Vaginal microflora
 Vaginal pH 4.3 0.4 4.4 0.3 .82 .85
 Nugent score 2.5 2.8 2.8 3.0 .85 .66
*

p-Value of visit adjusted for race, study, and contraceptive use/sexual practices.

AUC, area under the curve; CVL, cervicovaginal lavage; EPI, epithelium; HIV, human immunodeficiency virus; LP, lamina propria.